However, we demonstrated that high expression of hsa-mir-101-3p has an overall adverse survival for BC patients, which indicated that hsa-mir-101-3p might be a protective factor having a negative relation with DLGAP5 in BC patients. Here, DLGAP5 is linked to breast cancer.